Personalis (PSNL) AI Stock Analysis

• Market Cap: $498.15M
• Dividend Yield: N/A
• Average Volume (3M): 1.40M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.44
• Revenue Growth: 0.36%
• EPS Growth: 22.13%
• Country: US
• Employees: 228
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.23
• Shares Outstanding: 88,325,134
• 10 Day Avg. Volume: 865,661
• 30 Day Avg. Volume: 1,395,292
• PEG Ratio: 0.11
• Price to Book (P/B): 1.69
• Price to Sales (P/S): 4.05
• P/FCF Ratio: -7.33
• Enterprise Value/Market Cap: 0.90
• Enterprise Value/Revenue: 7.14
• Enterprise Value/Gross Profit: 55.95
• Enterprise Value/Ebitda: -5.29
• 1Y Price Target: $7.07
• Price Target Upside: 55.73% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 49 Neutral
• Price Target: $5.50 ▲(21.15% Upside)

Personalis faces significant challenges with profitability and negative cash flow, reflected in a low valuation score. Technical indicators suggest bearish momentum, further impacting the stock's attractiveness. However, strong clinical adoption, a robust cash position, and strategic partnerships provide some optimism for future growth.

Positive Factors

Clinical Testing Growth

PSNL drove strong 59% quarter-over-quarter growth of its clinical tests with its partner Tempus, highlighting robust demand in this segment.

MRD Technology Recognition

Growing optimism towards Personalis' opportunity in MRD and its solid pharma business supports a favorable outlook.

Pharma Contracts and Demand

PSNL has had recent wins with pharma companies, signing two MRD contracts with biopharma companies expected to contribute $5 million each this year.

Negative Factors

Biopharma and Enterprise Sales Decline

Revenue growth slowed to a decline as biopharma and enterprise sales more than offset growth in other areas.

Revenue Miss and Guidance Reduction

PSNL reported total revenues of $17.2M, below the consensus estimate of $20.1M, and management lowered their 2025 revenue guidance.

Translational Pharma Services Weakness

PSNL specifically called out softness in the translational side of its pharma services business, including from Moderna, leading to lower guidance.

Personalis Business Overview & Revenue Model

Company Description

Personalis, Inc. (PSNL) is a leading genomics company that specializes in advanced genomic sequencing and analytics. The company operates primarily in the healthcare and biotechnology sectors, offering comprehensive solutions for genetic testing and analysis. Its core products and services include genomic testing for cancer and other genetic disorders, which are utilized by researchers, healthcare providers, and pharmaceutical companies for precision medicine and customized treatment plans.

How the Company Makes Money

Personalis makes money through a revenue model that primarily revolves around providing genomic sequencing services and data analytics to various clients, including healthcare institutions, pharmaceutical companies, and research organizations. The company generates revenue by charging for its sequencing services, which involve analyzing and interpreting genomic data to aid in diagnostic and therapeutic decision-making. Key revenue streams include sales of genomic tests, licensing of proprietary technology, and partnerships with pharmaceutical firms for drug development and clinical trials. Additionally, Personalis engages in collaborations and contracts with government and private entities, contributing to its earnings by leveraging its expertise in genomics to support precision medicine initiatives.

Personalis Financial Statement Overview

Summary

Personalis displays mixed financial health with strong equity positions, yet struggles with profitability and cash flow negativity. Revenue growth provides some optimism, but operational losses and cash flow issues are concerning. The company must strategically manage costs and leverage growth opportunities to improve financial performance.

Income Statement

The company shows a mixed performance on the income statement. The TTM (Trailing-Twelve-Months) Gross Profit Margin stands at 33.31%, which indicates a reasonable level of profitability, albeit with high operational costs reflected in negative EBIT and EBITDA margins. The Net Profit Margin is significantly negative at -98.10%, highlighting ongoing losses. Revenue growth is positive at 3.20% year-over-year, suggesting some potential for future revenue expansion despite current challenges.

Balance Sheet

Personalis maintains a solid balance sheet, with a Debt-to-Equity ratio of 0.21, indicating low leverage and financial stability. The Equity Ratio is strong at 75.88%, showing substantial equity funding. However, despite a positive Return on Equity of -40.54%, the company operates at a loss, impacting overall financial health.

Cash Flow

Cash flow analysis reveals challenges with negative free cash flow, though the Free Cash Flow to Net Income Ratio of 0.56 suggests some alignment between cash outflows and net loss. The Operating Cash Flow to Net Income Ratio at 0.51 indicates cash operations are not fully supporting net income, a risk factor for liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	63.11M	84.61M	73.48M	65.05M	85.49M	78.65M
Gross Profit	8.05M	26.82M	18.21M	13.35M	31.66M	20.11M
EBITDA	-85.13M	-70.30M	-96.81M	-104.64M	-59.01M	-34.05M
Net Income	-91.32M	-81.28M	-108.30M	-113.31M	-65.23M	-41.28M
Balance Sheet
Total Assets	258.68M	270.27M	225.10M	292.70M	396.53M	244.84M
Cash, Cash Equivalents and Short-Term Investments	173.23M	185.01M	114.18M	167.66M	287.06M	203.29M
Total Debt	33.39M	44.25M	48.96M	48.65M	52.80M	10.99M
Total Liabilities	67.85M	67.31M	95.66M	74.56M	86.23M	49.90M
Stockholders Equity	190.83M	202.96M	129.44M	218.14M	310.30M	194.94M
Cash Flow
Free Cash Flow	-49.18M	-46.75M	-67.17M	-120.13M	-81.91M	-45.90M
Operating Cash Flow	-44.89M	-45.15M	-56.26M	-70.23M	-70.83M	-42.65M
Investing Cash Flow	-81.28M	-35.07M	13.10M	52.54M	-60.07M	-65.14M
Financing Cash Flow	131.79M	114.67M	11.03M	1.37M	169.70M	121.27M

Personalis Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.54
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PSNL, the sentiment is Negative. The current price of 4.54 is below the 20-day moving average (MA) of 5.96, below the 50-day MA of 5.99, and below the 200-day MA of 4.86, indicating a bearish trend. The MACD of -0.35 indicates Positive momentum. The RSI at 31.04 is Neutral, neither overbought nor oversold. The STOCH value of 23.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PSNL.

Personalis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TWST	56 Neutral	$1.66B	―	-17.58%	―	22.72%	62.11%
Sector *	51 Neutral	$7.39B	0.36	-62.86%	2.36%	15.48%	-2.68%
MYGN	51 Neutral	$522.65M	―	-70.03%	―	3.83%	-137.31%
PSNL	49 Neutral	$498.15M	―	-60.26%	―	0.36%	22.13%
GH	49 Neutral	$5.56B	―	-4584.47%	―	28.74%	18.25%
NEOG	45 Neutral	$1.04B	―	-41.88%	―	-2.50%	-30760.27%
OPK	44 Neutral	$1.01B	―	-13.16%	―	-7.31%	29.84%

Personalis Corporate Events

Personalis Expands Agreement with Tempus AI for Cancer Test

On July 8, 2025, Personalis, Inc. and Tempus AI, Inc. amended their existing agreement to include colorectal cancer as a new indication for the NeXT Personal® test, alongside breast cancer, lung cancer, and immuno-oncology monitoring. The amendment extends the exclusivity period for marketing the test and modifies certain standstill restrictions, potentially strengthening Personalis’ market position in cancer diagnostics.

The most recent analyst rating on (PSNL) stock is a Buy with a $7.25 price target. To see the full list of analyst forecasts on Personalis stock, see the PSNL Stock Forecast page.

Personalis Holds Virtual Annual Stockholders Meeting

On May 16, 2025, Personalis, Inc. held its annual meeting of stockholders virtually, with 87% of shares represented. During the meeting, stockholders elected two Class III directors, ratified the selection of BDO USA, P.C. as the independent auditor for 2025, and approved the executive compensation on an advisory basis.

The most recent analyst rating on (PSNL) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on Personalis stock, see the PSNL Stock Forecast page.